ClinicalTrials.Veeva

Menu

Pressure and Diabetic Foot (PIV & MPP)

Civil Hospices of Lyon logo

Civil Hospices of Lyon

Status

Enrolling

Conditions

Diabetes and Risk of Diabetic Foot Ulcer

Treatments

Other: Measure of cutaneous microcirculation

Study type

Interventional

Funder types

Other

Identifiers

NCT03213093
69HCL16_0168

Details and patient eligibility

About

Diabetic foot ulcer (DFU) is a worldwide burden in the management of patients with diabetes. Peripheral neuropathy has a key role in the physiopathology of DFU. Others factors as skin vulnerability to plantar pressure, glycation of skin protein, articular rigidity, vascular component and abnormal foot plantar pressure are also important to take into account. The aim of the study is to assess prospectively different factors involved in DFU pathogenesis notably the neurovascular response to non noxious pressure.

Enrollment

200 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age >18 years
  • Type 2 diabetic subject
  • Absence of active diabetic foot ulcer
  • Patients "Grade 0", "Grade 1", "Grade 2" or "Grade 3" of the International Working Group on Diabetic Foot Risk Classification defined by:
  • absence of alteration of perception of Monofilament 10g at the level of the plantar arch for the "grade 0"
  • alteration of perception of Monofilament 10g at the level of the plantar arch for the "grade 1"
  • alteration of perception of Monofilament 10g at the level of the plantar arch associated with foot deformity and / or an arteriopathy defined by the absence of perception of one of the two peripheral pulses for the "grade 2"
  • History of diabetic foot ulcer for the "grade 3"
  • Signature of consent to participate in the study

Exclusion criteria

  • Chronic alcoholism with usual consumption of at least 5 alcoholic drinks per day
  • Pregnancy
  • Congenital methemoglobinemia.
  • Porphyria
  • Skin injured on the tibia, whatever the lesion
  • Recent major cardiovascular history (less than 3 months)
  • Severe renal disease (serum creatinine> 300 μmol.l-1)

Trial design

Primary purpose

Screening

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

200 participants in 1 patient group

Diabetic patients with a risk of diabetic foot ulcer
Other group
Treatment:
Other: Measure of cutaneous microcirculation

Trial contacts and locations

1

Loading...

Central trial contact

Julien Vouillarmet

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems